Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

9,941 public trials 2,019 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Active, Not Recruiting

DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL

NCT03620578

Conditions
BCL-2 Translocation, Hemic and Lymphatic Diseases, High-grade B-cell Lymphoma, +11 more
Locations
  • BE-Antwerpen-ZNASTUIVENBERG Antwerp, Belgium
  • BE-Leuven-UZLEUVEN Leuven, Belgium
  • NL-Den Bosch-JBZ 's-Hertogenbosch, Netherlands
  • NL-Almere-FLEVOZIEKENHUIS Almere Stad, Netherlands
View all 24 locations
View Trial Details
Active, Not Recruiting

Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma

NCT05214183

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Department of Hematology X, Odense University Hospital Odense, Denmark
  • Department of Hematology, Zeeland University Hospital Roskilde Roskilde, Denmark
  • Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center Helsinki, Finland
  • Oulu University Hospital Oulu, Finland
View all 20 locations
View Trial Details
Active, Not Recruiting

Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)

NCT03915184

Conditions
Blood Protein Disorders, Carcinoma, Cardiovascular Diseases, +14 more
Locations
  • Mayo Clinic Hospital Phoenix, Arizona, United States
  • UCSF San Francisco, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View all 13 locations
View Trial Details
Active, Not Recruiting

Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant

NCT03289299

Conditions
Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +9 more
Locations
  • Moffitt Cancer Center Tampa, Florida, United States
  • University of Chicago Medical Center Chicago, Illinois, United States
  • Indiana University Simon Cancer Center Indianapolis, Indiana, United States
  • University of Kansas Cancer Center Westwood, Kansas, United States
View Trial Details
Active, Not Recruiting

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma

NCT04718883

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations
  • Peking University Cancer Hospital Beijing, Beijing Municipality, China
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • Fujian Medical University Consonancy Hospital Fuzhou, Fujiang, China
  • Guangdong Province people hospital Guanzhou, Guangdong, China
View Trial Details

Related conditions